No profile data available.
Liminatus Pharma, Inc. (LIMN) is a healthcare company in the additional cancer treatment drugs industry, based in Cerritos, United States, with about 1 full-time employees.
It reported revenue of $0 for fiscal year 2025, and net income of -$10.21 million. In Q2 2026 (the quarter ended June 30, 2026) revenue was $0. Its market capitalization was $5.05 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, a pre-clinical stage biopharmaceutical company, engages in the development of cancer therapies in the United States. It develops IBA101, a humanized anti CD47 monoclonal antibody, which is in Phase I clinical trial for the treatment of advanced solid cancers, including non-small cell lung cancer.
Liminatus Pharma reported $0 in revenue for fiscal year 2025. In Q2 2026 revenue was $0.
$5.05 million as of October 9, 2026.
Listed companies of a similar size in the same industry (additional cancer treatment drugs) include Aprea Therapeutics, Inc. (APRE), Traws Pharma, Inc. (TRAW), Imunon, Inc. (IMNN), NuCana plc (NCNA).